

File No: BIO/CT/18/000034  
Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organization  
(Biological Division)

To,

M/s. Intas Pharmaceuticals Ltd.,  
2<sup>nd</sup> Floor, Chinubhai Centre Off. Nehru Bridge,  
Ashram Road Ahmedabad Gujarat (India) – 380009

Subject: Permission for conducting a Phase 1 clinical trial titled "A randomized, double-blind, three-treatment, single-dose, parallel group, bioequivalence study of biosimilar Bevacizumab of Intas Pharmaceuticals Limited, India with Avastin™ in normal adult healthy volunteers."

Reference:- Your Application No. BIO/Form44/FF/2018/7997 dated 09-MAY-2018 on the subject mentioned above.

Sir,

This Directorate has no objection to your conducting subject mentioned study under the provisions of Drugs and Cosmetics Rules 122-DA and 122-DAC, under the supervision of the investigators mentioned below as per Protocol No.: 0446-16 Version No. 2.0 Protocol Date 03-MAY-2018 submitted to this Directorate.

Name of Investigator	Clinical Trial Site address	Name and Address of the Ethics Committee
DR. Akash Patel	Lambda Therapeutic Research Ltd. Lambda house, Plot No. 38, Survey No. 388, Near Silver Oak Club, S. G. Highway, Gota, Ahmedabad -382481, Gujarat, India	Conscience Independent Ethics Committee, D-1113, Titanium City Centre, 100 feet road, Nr. Sachin Tower, Satellite, Ahmadabad-380 015

Licensing Authority as defined in clause (b) of Rule 21, issue permission for conduct of clinical trial, subject to the following conditions further, namely:-

- (a) Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y annexed to these rules, Good Clinical Practice Guidelines for conduct of clinical trials in India and other applicable regulations;
- (b) Approval of the Ethics Committee shall be obtained before initiation of the study;
- (c) Clinical trial shall be registered at Clinical Trials Registry of India before enrolling the first patient for the study;
- (d) Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority;

(e) Any report of serious adverse event occurring during clinical trial to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y;

(f) In case of an injury or death during the clinical trial to the subject of the clinical trial the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with Rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority;

(g) The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trials in India and other applicable regulations;

(h) The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites and the investigator shall allow officers authorized by the Central Drug Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs etc. related to clinical trials and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial;

(I) Submit complete report of clinical trials as per the approved protocol from the individual investigator duly signed by him along with his observations/remarks on the drug.

(j) Indicating the date of commencement and conclusion of the clinical trial at each center (in case the study is multicentric).

It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

It is informed that all the amendments to Rule 122DAA, inclusion of Rule 122DAB, compensation matters etc. that are appended to the Drugs & Cosmetics Act & Rule, vide GSR 53 (E) dated 30.01.2013 and in Part X-A, after Rule 122DAB, Rule 122 DAC vide GSR 63 (E) dated 01.02.2013 are mandatory and binding.

Yours faithfully,

(Dr. S. Eswara Reddy)  
Drugs Controller General (I)